Drugs / Miransertib
Miransertib
also known as
ARQ 092 · MK-7075 · ARQ 092 FREE BASE · ARQ 092 mesylate · Miransertib bismesylate · Miransertib dimesylate · MIRANSERTIB MESYLATE
Small molecule targets AKT1, AKT2, AKT3 via inhibition
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02594215 | Nov 2015 → Dec 2017 | Proteus syndrome | National Human Genome Research Institute (NHGRI) | Completed | No outcome recorded |
| Phase 1 | NCT02476955 | Jun 2015 → May 2019 | endometrial cancer, ovarian cancer | ArQule, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01473095 | Nov 2011 → Jul 2017 | lymphoma | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03094832 | May 2017 → Apr 2022 | overgrowth syndrome | ArQule, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04316546 | May 2022 → Jun 2026 overdue | Proteus syndrome | National Human Genome Research Institute (NHGRI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04980872 | Nov 2021 → Feb 2030 expected | overgrowth syndrome | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03317366 | — | PIK3CA-related overgrowth spectrum, Proteus syndrome | ArQule, Inc. | No longer available | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Miransertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04980872 ↗ |
| Known as | ARQ 092 | “Miransertib (MK-7075, formerly ARQ 092) is a novel, orally bioavailable allosteric pan-AKT inhibitor” PMID 42224880 ↗ May 20264“MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT” NCT02594215 ↗ |
| Known as | ARQ 092 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297188 ↗ |
| Known as | ARQ 092 mesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297188 ↗ |
| Known as | Miransertib bismesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297188 ↗ |
| Known as | Miransertib dimesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297188 ↗ |
| Known as | MIRANSERTIB MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297188 ↗ |
| Known as | MK-7075 | “Miransertib (MK-7075, formerly ARQ 092) is a novel, orally bioavailable allosteric pan-AKT inhibitor” PMID 42224880 ↗ May 20261“has developed a small molecule, miransertib (MK-7075) that effectively inhibits AKT” NCT02594215 ↗ |
| Action | Inhibit | “The multicenter, open-label, phase 1/2 MOSAIC study (NCT03094832) was designed to evaluate the clinical efficacy and safety of the selective pan-AKT inhibitor miransertib for...” PMID 40713644 ↗ Jul 2025 |
| Modality | Small molecule | “has developed a small molecule, miransertib (MK-7075) that effectively inhibits AKT” NCT02594215 ↗ |
| Route | Oral | “ARQ 092 orally” NCT01473095 ↗ |
| Target | AKT1 | “Clinical experience with the AKT1 inhibitor miransertib in two children with” PMID 33639990 ↗ Feb 2021 |